

### **AMENDMENTS TO THE SPECIFICATION**

#### (1) Amendments to the Sequence Listing

Submitted herewith is a Substitute Sequence Listing in paper and computer readable form (CRF) to replace the Sequence Listing filed during the International Stage of the present application.

Applicants also submit herewith a "Submission of Substitute Sequence Listing and Statement under 37 C.F.R. §§ 1.821-1.825".

#### (2) Amendments to the Specification

Please replace the paragraph at page 7, line 26 through page 8, line 2, with the following paragraph:

-- Since there are ethical objections to sensitivity measurement tests using the brains of Alzheimer's patients, another evaluation system needs to be used for evaluating the sensitivity of the secretase inhibitor. The inventors therefore used an evaluation system in which cells were treated with a secretase inhibitor and cell proliferation was used as the marker of secretase inhibition. There are no particular limits on the type of secretase here, and examples include  $\beta$ -secretase and  $\gamma$ -secretase. Consequently, the secretase inhibitor can be either a  $\beta$ -secretase inhibitor or a  $\gamma$ -secretase inhibitor. There are no particular limits on the secretase inhibitor, and examples include L-685,458 (Peptide Institute), (3,5-Difluorophenylacetyl)-Ala-Phg-OBu<sup>t</sup> [DAPT] (Peptide Institute), Lys-Thr-Glu-Glu-Ile-Ser-Glu-Val-Asn-Sta-Val-Ala-Glu-Phe (SEQ ID NO:21) (Peptide Institute), Z-Leu-Leu-Nle-CHO (Wako) and the like. --